Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
lactoserum · 4 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| lactoserum | DRUG | - |
The following information on clinical trials is provided for information purposes only to allow patients and physicians to have an initial discussion about the trial. This information is not intended to be complete information about the trial, to contain all considerations that may be relevant to po...
Lactoserum is a small molecule developed by Sanofi (ticker SNY) that has been studied in Phase 3 trials in Brazil. The completed trials evaluated it in personal hygiene products, including Dermacyd wipes and Dermacyd Delicata products, in healthy adult volunteers.
Lactoserum has been studied for use in hygiene products, specifically in Dermacyd wipes and Dermacyd Delicata formulations. The Phase 3 trials assessed acceptability and topical compatibility in healthy adult volunteers rather than testing it as a treatment for a disease.
Lactoserum is developed by Sanofi, which trades under the ticker SNY. Sanofi sponsored the Phase 3 trials of lactoserum conducted in Brazil, which examined the agent in Dermacyd hygiene products including wipes and Delicata formulations.
Lactoserum has been studied in Phase 3 clinical trials. Four Phase 3 trials have been completed, and none are currently active. The trials enrolled a total of 160 participants and were conducted in Brazil.
Lactoserum has been evaluated in four completed Phase 3 trials: NCT00397527, NCT00380991, NCT00371852, and NCT00370162. These trials studied Dermacyd wipes and Dermacyd Delicata products containing lactoserum in healthy adult volunteers in Brazil.
The lactoserum Phase 3 trials were uncontrolled and not double blinded. They were not randomized and enrolled healthy volunteers rather than patients selected by biomarker. Total enrollment across the four completed trials was 160 participants, all conducted in Brazil.